Bayer (FRA:BAYN) has been assigned a €105.00 ($129.63) target price by stock analysts at Kepler Capital Markets in a report issued on Monday. The brokerage presently has a “neutral” rating on the healthcare company’s stock. Kepler Capital Markets’ price target points to a potential upside of 7.38% from the stock’s previous close.
Several other brokerages also recently commented on BAYN. UBS Group set a €125.00 ($154.32) target price on shares of Bayer and gave the stock a “buy” rating in a research note on Monday, November 6th. Berenberg Bank set a €124.00 ($153.09) target price on shares of Bayer and gave the stock a “neutral” rating in a research note on Tuesday, December 5th. Warburg Research set a €121.00 ($149.38) target price on shares of Bayer and gave the stock a “neutral” rating in a research note on Thursday, January 11th. Jefferies Group set a €125.00 ($154.32) price objective on shares of Bayer and gave the company a “buy” rating in a research report on Monday. Finally, JPMorgan Chase & Co. set a €128.00 ($158.02) price objective on shares of Bayer and gave the company a “buy” rating in a research report on Thursday, January 4th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and fourteen have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of €121.86 ($150.44).
Bayer (FRA BAYN) opened at €97.78 ($120.72) on Monday. Bayer has a one year low of €93.30 ($115.19) and a one year high of €123.82 ($152.86). The company has a market cap of $80,610.00 and a price-to-earnings ratio of 23.12.
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.